Comprehensive genetic assessment of the estrogen receptor 1 (ESR1) locus identifies a risk region for endometrial cancer


1 Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.
2 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.
3 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK.
4 Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW, 2305, Australia.
5 Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, 2305, Australia.
6 Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, 2305, Australia.
7 Centre for Information Based Medicine, University of Newcastle, Newcastle, NSW, 2308, Australia.
8 School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, 2308, Australia.
9 School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, 2308, Australia.
10 Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK.
11 Department of Clinical Genetics, St George's Hospital Medical School, London, SW17 0RE, UK.
12 University of California at Los Angeles, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Los Angeles, CA, 90095, USA.
13 Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, 91054, Germany.
14 Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, 91054, Germany.
15 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, SE-171 77, Sweden.
16 Department of Gynaecology, Jena University Hospital - Friedrich Schiller University, Jena, 07743, Germany.
17 Hannover Medical School, Clinics of Gynaecology and Obstetrics, Hannover, 30625, Germany.
18 Hannover Medical School, Gynaecology Research Unit, Hannover, 30625, Germany.
19 Van Deusen Research Center, Leuven, 3000, Belgium.
20 Laboratory for Translational Genetics, Department of Oncology, University Hospitals Leuven, Leuven, 3000, Belgium.
21 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals, KU Leuven - University of Leuven, 3000, Belgium.
22 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.
23 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
24 Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
25 Centre for Cancerbiomarkers, Department of Clinical Science, The University of Bergen, 5020, Norway.
Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, 5021, Norway.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SE-171 77, Sweden.
Department of Women’s and Children’s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, SE-171 77, Sweden.
Department of Cancer Epidemiology, Division of Population Sciences, Moffitt Cancer Center, Tampa, FL, 33612, USA.
Department of Community and Family Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Vic, 3010, Australia.
Peter MacCallum Cancer Center, The University of Melbourne, Melbourne, 3002, Australia.
London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Division of Genetics and Epidemiology, Institute of Cancer Research, London, SM2 5NG, UK.
Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, 69120, Germany.
Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, 69120, Germany.
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
Department of Obstetrics and Gynecology, Division of Tumor Genetics, Technical University of Munich, Munich, 80333, Germany.
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, 70376, Germany.
University of Tübingen, Tübingen, 72074, Germany.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Vic, 3004, Australia.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, 3004, Australia.
Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, 0310, Norway.
The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 0316, Norway.
Department of Clinical Molecular Oncology, Division of Medicine, Akershus University Hospital, Lørenskog, 1478, Norway.
Sheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield, S10 2RX, UK.

* To whom correspondence should be addressed. Tel: +61 7336 20371; Fax: +61 7336 20111; Email: Amanda.Spurdle@qimrberghofer.edu.au
SUPPLEMENTARY INFORMATION

Contents
  A. ECAC Study Collaborators (for case samples):.................................................................2
  B. BCAC and OCAC Study Collaborators (for control samples):......................................2
  C. Supplementary Acknowledgements..............................................................................3
A. ECAC Study Collaborators (for case samples):

The ANECS Group comprises:


The NSECG Group comprises:


RENDOCAS investigators include: Annika Lindblom, Gerasimos Tzortzatos, Miriam Mints, Emma Tham, Ofra Castro, Kristina Gemzell-Danielsson.

SEARCH collaborators include:

Helen Baker, Caroline Baynes, Don Conroy, Bridget Curzon, Patricia Harrington, Sue Irvine, Craig Luccarini, Rebecca Mayes, Hannah Munday, Barbara Perkins, Daisy Pharoah, Radka Platte, Anne Stafford and Judy West.

B. BCAC and OCAC Study Collaborators (for control samples):


BSUCH collaborator: Peter Bugert.

ESTHER collaborators: Volker Arndt, Heiko Müller, Christa Stegmaier.

GENICA Network collaborators: Wing-Yee Lo, Christina Justenhoven, Ute Hamann, Thomas Brüning, Beate Pesch, Yon-Dschun Ko, Sylvia Rabstein, Anne Lotz, Christina Baisch, Hans-Peter Fischer, Volker Harth.

C. Supplementary Acknowledgements

The authors thank the many individuals who participated in this study and the numerous institutions and their staff who have supported recruitment.

ANECS thanks members of the Molecular Cancer Epidemiology and Cancer Genetic laboratories at QIMR Berghofer Medical Research Institute for technical assistance, and the ANECS research team for assistance with the collection of risk factor information and blood samples. ANECS also gratefully acknowledges the cooperation of the following institutions: NSW: John Hunter Hospital, Liverpool Hospital, Mater Misericordiae Hospital (Sydney), Mater Misericordiae Hospital (Newcastle), Newcastle Private Hospital, North Shore Private Hospital, Royal Hospital for Women, Royal Prince Alfred Hospital, Royal North Shore Hospital, Royal Prince Alfred Hospital, St George Hospital; Westmead Hospital, Westmead Private Hospital; Qld: Brisbane Private Hospital, Greenslopes Hospital, Mater Misericordiae Hospitals, Royal Brisbane and Women's Hospital, Wesley Hospital, Queensland Cancer Registry; SA: Adelaide Pathology Partners, Burnside Hospital, Calvary Hospital, Flinders Medical Centre, Queen Elizabeth Hospital, Royal Adelaide Hospital, South Australian Cancer Registry; Tas: Launceston Hospital, North West Regional Hospitals, Royal Hobart Hospital; Vic: Freemasons Hospital, Melbourne Pathology Services, Mercy Hospital for Women, Royal Women's Hospital, Victorian Cancer Registry; WA: King Edward Memorial Hospital, St John of God Hospitals Subiaco & Murdoch, Western Australian Cancer Registry.

SEARCH thanks the SEARCH research team for recruitment, and also acknowledges the assistance of the Eastern Cancer Registration and Information Centre for subject recruitment.

BECS thanks Reiner Strick, Silke Landrith and Sonja Oeser for their logistic support during the study.

CAHRES (formerly known as SASBAC) thanks Li Yuqing from the Genome Institute of Singapore for contributions to this study, and also acknowledges previous input to SASBAC resource creation by Anna Christensson, Boel Bissmarck, Kirsimari Aaltonen, Karl von Smitten, Nina Puolakka, Christer Halldén, Lim Siew Lan and Irene Chen, Lena U. Rosenberg, Mattias Hammarström, and Eija Flygare.

HJECS thanks Wen Zheng, Hermann Hertel, and Tjoung-Won Park-Simion at Hannover Medical School for their contribution to sample recruitment.

LES gratefully acknowledges Helena Soenen, Gilian Peuteman and Dominiek Smeets for their technical assistance.

MECS thanks Tom Sellers, Catherine Phelan, Andrew Berchuck, and Kimberly Kalli, Amanda von
Bismarck, Luisa Freyer and Lisa Rogmann.

MoMaTEC thanks Britt Edvardsen, Ingjerd Bergo and Mari Kyllsø Halle for technical assistance and Inger Marie Aksnes and Tor Audun Hervig at the Blood bank, Haukeland University Hospital for assistance with control recruitment.

NECS thanks staff at the University of Newcastle and the Hunter Medical Research Institute.

NSEC thank Ella Barclay and Lynn Martin for their contribution, and acknowledge the invaluable help of the National Cancer Research Network with the collection of study participants.

QIMR Berghofer thanks Margie Wright, Lisa Bowdler, Sara Smith, Megan Campbell and Scott Gordon for control sample collection and data processing, Kerenaftert Klein for statistical advice and Brendan Ryan for assistance with the figures.

RENDOCAS thanks Berith Wejderot, Sigrid Sahlen, Tao Liu, Margareta Ström, Maria Karlsson, and Birgitta Byström for their contribution to the study.

BSUCH thanks the Medical Faculty, Mannheim, the Diemtmar Hopp Foundation and the German Cancer Research Center.

MCCS was made possible by the contribution of many people, including the original investigators and the diligent team who recruited the participants and who continue working on follow up. We would like to express our gratitude to the many thousands of Melbourne residents who continue to participate in the study.

The UKBGS thank Breakthrough Breast Cancer and the Institute of Cancer Research for support and funding, and the Study participants, Study staff, and the doctors, nurses and other health care staff and data providers who have contributed to the Study. The ICR acknowledges NHS funding to the NIHR Biomedical Research Centre.

In addition, the iCOGS study would not have been possible without the contributions of: Andrew Berchuck (OCAC), Rosalind A. Eeles, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Cancer Genetic Epidemiology Laboratory (Cambridge), Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility.